» Articles » PMID: 31676661

Prognostic Factors for Relapse in Patients with Clinical Stage I Testicular Cancer: Protocol for a Danish Nationwide Cohort Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2019 Nov 3
PMID 31676661
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Approximately one-fourth of patients with clinical stage I testicular germ cell cancer will relapse within 5 years of follow-up. Certain histopathological features in the primary tumour have been associated with an increased risk of relapse. The available evidence on the prognostic value of the risk factors, however, is hampered by heterogeneity of the study populations included and variable reporting of the histopathological features. The aim of this study is to identify pathological risk factors for relapse in an unselected large nationwide cohort of patients with stage I disease.

Methods And Analysis: All incident cases of stage I testicular germ cell cancer diagnosed in Denmark between 2013 and 2018 will be identified using the nationwide prospective Danish Testicular Cancer (DaTeCa) database. Archived microscopic slides from the orchiectomy specimens will be retrieved through linkage to the Danish Pathology Data Bank and reviewed blinded to the clinical outcome. The DaTeCa database includes 960 stage I seminoma patients with expected 185 relapses and 480 patients with stage I non-seminoma with expected 150 relapses. A minimum follow-up period of 3 years of all patients will be ensured. Predefined prognostic variables will be investigated with regard to relapse in univariable and multivariable analysis using the Cox proportional hazards model.

Ethics And Dissemination: This study protocol has been approved by the Regional Ethics Committee (Region Zealand, Denmark) and the Danish Data Protection Agency. All data will be managed confidentially according to legislation. Study results will be presented at international conferences and published in peer-review journals.

Citing Articles

Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study.

Lindahl N, Lauritsen J, Wagner T, Daugaard G, Bandak M Acta Oncol. 2025; 64:191-199.

PMID: 39886914 PMC: 11811535. DOI: 10.2340/1651-226X.2025.42281.


A Validated Algorithm for Register-Based Identification of Patients with Relapse of Clinical Stage I Testicular Cancer.

Wagner T, Lauritsen J, Bandak M, Rasmussen L, Bakker J, Hovaldt H Clin Epidemiol. 2023; 15:447-457.

PMID: 37041861 PMC: 10083026. DOI: 10.2147/CLEP.S401737.


Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.

Lobo J, Constancio V, Guimaraes-Teixeira C, Leite-Silva P, Miranda-Goncalves V, Sequeira J Mol Oncol. 2021; 15(4):846-865.

PMID: 33513287 PMC: 8024740. DOI: 10.1002/1878-0261.12909.


Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of 'epidrugs'.

Cardoso A, Lobo J, Miranda-Goncalves V, Henrique R, Jeronimo C Epigenetics. 2020; 16(4):353-372.

PMID: 32749176 PMC: 7993192. DOI: 10.1080/15592294.2020.1805682.

References
1.
Lee A, Mead G, Theaker J . The value of central histopathological review of testicular tumours before treatment. BJU Int. 1999; 84(1):75-8. DOI: 10.1046/j.1464-410x.1999.00048.x. View

2.
Mortensen M, Lauritsen J, Gundgaard M, Agerbaek M, Holm N, Christensen I . A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014; 66(6):1172-8. DOI: 10.1016/j.eururo.2014.07.001. View

3.
Verrill C, Yilmaz A, Srigley J, Amin M, Comperat E, Egevad L . Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol. 2017; 41(6):e22-e32. DOI: 10.1097/PAS.0000000000000844. View

4.
Horwich A, Alsanjari N, AHern R, Nicholls J, Dearnaley D, Fisher C . Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992; 65(5):775-8. PMC: 1977398. DOI: 10.1038/bjc.1992.164. View

5.
Cohn-Cedermark G, Stahl O, Tandstad T . Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology. 2014; 3(1):102-10. DOI: 10.1111/andr.280. View